CO2021007647A2 - Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos - Google Patents

Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos

Info

Publication number
CO2021007647A2
CO2021007647A2 CONC2021/0007647A CO2021007647A CO2021007647A2 CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2 CO 2021007647 A CO2021007647 A CO 2021007647A CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2
Authority
CO
Colombia
Prior art keywords
nanoemulsification
production methods
cannabis oil
oil powder
powder formulated
Prior art date
Application number
CONC2021/0007647A
Other languages
English (en)
Inventor
Rafael Ezra
Liraz Larush
Shlomo Magdassi
Original Assignee
Karnak Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karnak Tech Llc filed Critical Karnak Tech Llc
Publication of CO2021007647A2 publication Critical patent/CO2021007647A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención describe una formulación sólida dispersable en agua particular de un cannabinoide o un extracto de cannabis, en donde se encuentran presentes en forma de nanoemulsión, y al dispersarse en agua dicha formulación produce nanopartículas (gotitas de un tamaño submicrónico) con un tamaño promedio de hasta aproximadamente 500 nm. La presente exposición se refiere además a métodos para su elaboración, así como a aplicaciones terapéuticas en seres humanos para tratar trastornos y una aplicación más amplia para una variedad de afecciones médicas.
CONC2021/0007647A 2018-08-13 2021-06-10 Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos CO2021007647A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (1)

Publication Number Publication Date
CO2021007647A2 true CO2021007647A2 (es) 2021-08-30

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007647A CO2021007647A2 (es) 2018-08-13 2021-06-10 Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos

Country Status (10)

Country Link
US (2) US11712430B2 (es)
EP (1) EP3716946A1 (es)
JP (1) JP2021535935A (es)
CN (1) CN113473965A (es)
AU (1) AU2019322212B2 (es)
BR (1) BR112021009869A2 (es)
CA (1) CA3086887A1 (es)
CO (1) CO2021007647A2 (es)
IL (2) IL261132A (es)
WO (1) WO2020035850A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020220141A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
WO2021028943A1 (en) * 2019-08-12 2021-02-18 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
AU2021317262A1 (en) 2020-07-29 2022-06-09 Rafael EZRA Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils
WO2022024127A1 (en) 2020-07-29 2022-02-03 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
US20230147292A1 (en) * 2020-07-29 2023-05-11 Karnak Technologies, Llc Improved formulations of lipophilic subtances for cosmetic uses
WO2022035682A1 (en) * 2020-08-14 2022-02-17 Lieberman Ori Dosing capsule made from cannabis-derived resin and methods of making the same
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528601A1 (en) * 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
DK2804587T3 (da) 2012-01-19 2019-08-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
WO2015171445A1 (en) 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
AU2016231788A1 (en) 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
AU2016347651A1 (en) * 2015-10-26 2018-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Novel cannabinoid formulations
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物

Also Published As

Publication number Publication date
JP2021535935A (ja) 2021-12-23
WO2020035850A1 (en) 2020-02-20
US20210059975A1 (en) 2021-03-04
IL275430A (en) 2020-08-31
US20230321031A1 (en) 2023-10-12
EP3716946A1 (en) 2020-10-07
AU2019322212B2 (en) 2022-09-29
AU2019322212A1 (en) 2021-04-08
CA3086887A1 (en) 2020-02-20
BR112021009869A2 (pt) 2022-05-17
CN113473965A (zh) 2021-10-01
IL261132A (en) 2018-11-04
US11712430B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CO2021007647A2 (es) Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos
CR20210483A (es) Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2018003432A1 (es) Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
BR112016013213A2 (pt) administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
CL2019000787A1 (es) Métodos para tratar trastornos mitocondriales y metabólicos.
HRP20201333T1 (hr) Kompozicija koja sadrži oleosome sa različitom raspodjelom veličina
PE20200726A1 (es) Composicion de cannabis
CO2021001061A2 (es) Composición y método para tratar el dolor
BR112019000130A2 (pt) formulação agrícola, formulação aquosa compreendendo a mesma, agente de tratamento agrícola, produto vegetal, método de tratamento de um alvo agrícola e método para reduzir a transmissão de uma doença fúngica de planta
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
ECSP18024466A (es) Composiciones de micropartículas que comprenden saflufenacil
CO2020013182A2 (es) Método y composición para el tratamiento de trastornos del snc
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
CO2017007962A1 (es) Nanoparticulas oleosas de cannabis microencapsuladas en polvo
DOP2019000060A (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
AR108935A1 (es) Extracto de aquenio de silybum marianum y sus usos en dermatología y dermocosmética
AR075686A1 (es) Nanoparticulas de policosanol
WO2018081183A3 (en) Maca compositions and methods of use
IT201700067430A1 (it) Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2016003376A1 (es) Metodo de preparacion de un catalizador de nanoparticulas de cu2o/tio2; y catalizador de nanoparticulas de cu2o/tio2